Victoria Osinski1,2, Prasad Srikakulapu3, Young Min Haider3, Melissa A Marshall3, Vijay C Ganta4, Brian H Annex4,5, Coleen A McNamara1,3,6. 1. Robert M. Berne Cardiovascular Research Center (V.O., C.A.M.), University of Virginia. 2. Department of Pathology (V.O.), University of Virginia. 3. Beirne B. Carter Center for Immunology Research (P.S., Y.M.H., M.A.M., C.A.M.), University of Virginia. 4. Vascular Biology Center (V.C.G., B.H.A.), Augusta University, GA. 5. Department of Medicine, Medical College of Georgia (B.H.A.), Augusta University, GA. 6. Division of Cardiovascular Medicine, Department of Medicine (C.A.M.), University of Virginia.
Abstract
OBJECTIVE: Neovascularization can maintain and even improve tissue perfusion in the setting of limb ischemia during peripheral artery disease. The molecular and cellular mechanisms mediating this process are incompletely understood. We investigate the potential role(s) for Id3 (inhibitor of differentiation 3) in regulating blood flow in a murine model of hindlimb ischemia (HLI). Approach and Results: HLI was modeled through femoral artery ligation and resection and blood flow recovery was quantified by laser Doppler perfusion imaging. Mice with global Id3 deletion had significantly impaired perfusion recovery at 14 and 21 days of HLI. Endothelial- or myeloid cell-specific deletion of Id3 revealed no effect on perfusion recovery while B-cell-specific knockout of Id3 (Id3BKO) revealed a significant attenuation of perfusion recovery. Flow cytometry revealed no differences in ischemia-induced T cells or myeloid cell numbers at 7 days of HLI, yet there was a significant increase in B-1b cells in Id3BKO. Consistent with these findings, ELISA (enzyme-linked immunoassay) demonstrated increases in skeletal muscle and plasma IgM. In vitro experiments demonstrated reduced proliferation and increased cell death when endothelial cells were treated with conditioned media from IgM-producing B-1b cells and tibialis anterior muscles in Id3BKO mice showed reduced density of total CD31+ and αSMA+CD31+ vessels. CONCLUSIONS: This study is the first to demonstrate a role for B-cell-specific Id3 in maintaining blood flow recovery during HLI. Results suggest a role for Id3 in promoting blood flow during HLI and limiting IgM-expressing B-1b cell expansion. These findings present new mechanisms to investigate in peripheral artery disease pathogenesis.
OBJECTIVE: Neovascularization can maintain and even improve tissue perfusion in the setting of limb ischemia during peripheral artery disease. The molecular and cellular mechanisms mediating this process are incompletely understood. We investigate the potential role(s) for Id3 (inhibitor of differentiation 3) in regulating blood flow in a murine model of hindlimb ischemia (HLI). Approach and Results: HLI was modeled through femoral artery ligation and resection and blood flow recovery was quantified by laser Doppler perfusion imaging. Mice with global Id3 deletion had significantly impaired perfusion recovery at 14 and 21 days of HLI. Endothelial- or myeloid cell-specific deletion of Id3 revealed no effect on perfusion recovery while B-cell-specific knockout of Id3 (Id3BKO) revealed a significant attenuation of perfusion recovery. Flow cytometry revealed no differences in ischemia-induced T cells or myeloid cell numbers at 7 days of HLI, yet there was a significant increase in B-1b cells in Id3BKO. Consistent with these findings, ELISA (enzyme-linked immunoassay) demonstrated increases in skeletal muscle and plasma IgM. In vitro experiments demonstrated reduced proliferation and increased cell death when endothelial cells were treated with conditioned media from IgM-producing B-1b cells and tibialis anterior muscles in Id3BKO mice showed reduced density of total CD31+ and αSMA+CD31+ vessels. CONCLUSIONS: This study is the first to demonstrate a role for B-cell-specific Id3 in maintaining blood flow recovery during HLI. Results suggest a role for Id3 in promoting blood flow during HLI and limiting IgM-expressing B-1b cell expansion. These findings present new mechanisms to investigate in peripheral artery disease pathogenesis.
Authors: Richard A Cohen; Colin E Murdoch; Yosuke Watanabe; Victoria M Bolotina; Alicia M Evangelista; Dagmar J Haeussler; Melissa D Smith; Yu Mei; XiaoYong Tong; Jingyan Han; Jessica B Behring; Markus M Bachschmid; Reiko Matsui Journal: J Cardiovasc Pharmacol Date: 2016-06 Impact factor: 3.105
Authors: Sotirios Tsimikas; Atsushi Miyanohara; Karsten Hartvigsen; Esther Merki; Peter X Shaw; Meng-Yun Chou; Jennifer Pattison; Michael Torzewski; Janina Sollors; Theodore Friedmann; N Chin Lai; H Kirk Hammond; Godfrey S Getz; Catherine A Reardon; Andrew C Li; Carole L Banka; Joseph L Witztum Journal: J Am Coll Cardiol Date: 2011-10-11 Impact factor: 24.094
Authors: Amanda C Doran; Michael J Lipinski; Stephanie N Oldham; James C Garmey; Kirsti A Campbell; Marcus D Skaflen; Alexis Cutchins; Daniel J Lee; David K Glover; Kimberly A Kelly; Elena V Galkina; Klaus Ley; Joseph L Witztum; Sotirios Tsimikas; Timothy P Bender; Coleen A McNamara Journal: Circ Res Date: 2011-10-27 Impact factor: 17.367
Authors: Carmen Fiuza; Michael Bustin; Shefali Talwar; Margaret Tropea; Eric Gerstenberger; James H Shelhamer; Anthony F Suffredini Journal: Blood Date: 2002-11-27 Impact factor: 22.113
Authors: Rodney K Chan; Grace Ding; Nicola Verna; Shahrul Ibrahim; Sean Oakes; William G Austen; Herbert B Hechtman; Francis D Moore Journal: J Surg Res Date: 2004-11 Impact factor: 2.192
Authors: Thomas A Prohaska; Xuchu Que; Cody J Diehl; Sabrina Hendrikx; Max W Chang; Kristen Jepsen; Christopher K Glass; Christopher Benner; Joseph L Witztum Journal: J Immunol Date: 2018-01-29 Impact factor: 5.422